Mankind Pharma Ltd
NSE:MANKIND
Mankind Pharma Ltd
Operating Income
Mankind Pharma Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Operating Income
₹21.5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Operating Income
₹67.7B
|
CAGR 3-Years
26%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Operating Income
₹58.2B
|
CAGR 3-Years
18%
|
CAGR 5-Years
22%
|
CAGR 10-Years
14%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Operating Income
₹122.5B
|
CAGR 3-Years
15%
|
CAGR 5-Years
22%
|
CAGR 10-Years
4%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Operating Income
₹37.3B
|
CAGR 3-Years
29%
|
CAGR 5-Years
17%
|
CAGR 10-Years
1%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Operating Income
₹28.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
14%
|
CAGR 10-Years
10%
|
|
Mankind Pharma Ltd
Glance View
Mankind Pharma Ltd. has carved a unique niche in the pharmaceutical landscape of India, emerging as a formidable entity through an intriguing blend of affordability and accessibility. Founded in 1995 by R. C. Juneja, the company has steadily grown its portfolio to encompass a vast range of pharmaceutical products spanning prescription medications, over-the-counter (OTC) drugs, and consumer healthcare goods. Operating with a distinctive business model rooted in the ethos of delivering quality medicine at affordable prices, Mankind Pharma reaches deep into the densely populated tier II and tier III cities of India, ensuring that healthcare is accessible to the masses who need it the most. This strategic outreach, coupled with strong marketing and distribution networks, serves as a cornerstone of its business success. The company’s financial health is buoyed by its diversified product range, which caters to multiple therapeutic areas including antibiotics, cardiovascular, antifungal, and gastrointestinal, among others. Their robust R&D initiatives further reinforce their competitive edge, enabling them to continually introduce new and effective products that resonate with both healthcare providers and consumers. Revenue streams are not just confined to domestic borders; Mankind Pharma has been expanding its footprint internationally, penetrating markets across Asia, Africa, and the Americas. By striking a strategic balance between volume-driven pricing models and extensive market reach, Mankind Pharma not only emphasizes profitability but also solidifies its commitment to public health initiatives globally, thus creating a sustainable and progressive business trajectory.
See Also
What is Mankind Pharma Ltd's Operating Income?
Operating Income
21.5B
INR
Based on the financial report for Mar 31, 2024, Mankind Pharma Ltd's Operating Income amounts to 21.5B INR.
What is Mankind Pharma Ltd's Operating Income growth rate?
Operating Income CAGR 3Y
11%
Over the last year, the Operating Income growth was 35%. The average annual Operating Income growth rates for Mankind Pharma Ltd have been 11% over the past three years .
You don't have any saved screeners yet